Effect of Admission and Onset Time on the Prognosis of Patients With Cardiogenic Shock

Michael Behnes1, Jonas Rusnak1, Sascha Egner-Walter1

  • 1Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany; European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim.

Chest
|August 14, 2023
PubMed

Insights

Cardiogenic shock (CS) patients admitted during off-hours had a lower risk of 30-day mortality. In-hospital CS related to acute myocardial infarction (AMI) increased mortality risk, while overall place of onset did not significantly impact outcomes.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Clinical Research

Background:

  • The patient demographic for cardiogenic shock (CS) has evolved, with an increasing prevalence of non-acute myocardial infarction (AMI) cases.
  • The impact of CS onset location (in-hospital vs. out-of-hospital) and timing (on-hours vs. off-hours) on mortality remains under-investigated.

Purpose of the Study:

  • To investigate the prognostic impact of CS onset location on 30-day all-cause mortality.
  • To determine if the timing of out-of-hospital CS admission (on-hours vs. off-hours) influences mortality risk.
  • To examine the association between AMI and non-AMI etiologies of CS and mortality outcomes.

Main Methods:

  • Prospective monocentric registry of consecutive CS patients from 2019-2021.
  • Kaplan-Meier analyses and univariable/multivariable Cox regression models were employed.
  • Analysis stratified by place of onset, timing of onset, and presence/absence of AMI.

Main Results:

  • No significant difference in 30-day mortality between primary (out-of-hospital) and secondary (in-hospital) CS overall (HR, 1.532; P = .06).
  • Secondary in-hospital CS associated with AMI showed increased 30-day mortality risk (HR, 2.087; P = .02).
  • Primary out-of-hospital CS admitted during off-hours demonstrated a significantly lower risk of 30-day mortality compared to on-hours admissions (HR, 0.497; P = .01).

Conclusions:

  • The location of CS onset (primary vs. secondary) did not significantly alter 30-day mortality, but AMI-related secondary CS carried a higher risk.
  • Out-of-hospital CS presenting during off-hours was associated with improved survival, irrespective of AMI.
  • These findings highlight the importance of considering CS onset timing and etiology for risk stratification and management.
Abstract

Related Concept Videos

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
89
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
12
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364